ArticleNeoplasia (New York, N.Y.)2010
How do bisphosphonates inhibit bone metastasis in vivo?
Article in Neoplasia (New York, N.Y.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 61 citations in OpenAlex.
- Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.BMC cancer · 2013Trial
- Ultrasound-assisted synthesis of new bisphosphonate-betulin conjugates and preliminary evaluation of their cytotoxic activity.RSC advances · 2025Article
- Superior bone regenerative properties of carbonate apatite with locational bone-active factors through an inorganic process.Regenerative therapy · 2024Article
- The Roadmap of RANKL/RANK Pathway in Cancer.Cells · 2021Review
- Synergistic effect of graphene oxide and zoledronic acid for osteoporosis and cancer treatment.Scientific reports · 2020Article
- An open-label, prospective, observational study of the efficacy of bisphosphonate therapy for painful osteoid osteoma.European radiology · 2018Observational
- Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation.Cell death & disease · 2017Article
- Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.Breast cancer research : BCR · 2017Article
- Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration.Journal of bone oncology · 2017Article
- Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole.Frontiers in pharmacology · 2017Article
- Fabrication and physicochemical characterization of porous composite microgranules with selenium oxyanions and risedronate sodium for potential applications in bone tumors.International journal of nanomedicine · 2017Article
- Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients.BMC cancer · 2016Article
- Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma.Journal of veterinary internal medicine · 2016Article
- Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.International journal of cancer · 2016Article
- Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence.Breast cancer research : BCR · 2015Review
- Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Observational
- Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells.Cancer genetics · 2015Article
- Circulating tumor cell count during zoledronic acid treatment in men with metastatic prostate cancer: a pilot study.Prostate international · 2014Article
- Human isoprenoid synthase enzymes as therapeutic targets.Frontiers in chemistry · 2014Review
- Bone-targeted therapies for elderly patients with renal cell carcinoma: current and future directions.Drugs & aging · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and have demonstrated clinical utility in the treatment of patients with osteolytic bone metastases. They also exhibit direct antitumor activity in vitro and can reduce skeletal tumor burden and inhibit the formation of bone metastases in vivo. However, whether such effects are caused by a direct action of bisphosphonates on tumor cells or indirectly through inhibition of bone resorption remains unclear. To address this question, we used here a structural analog of the bisphosphonate risedronate, NE-58051, which has a bone mineral affinity similar to that of risedronate, but a 3000-fold lower bone antiresorptive activity. In vitro, risedronate and NE-58051 inhibited proliferation of breast cancer and melanoma cell lines. In vivo, risedronate and NE-58051 did not inhibit the growth of subcutaneous B02 breast tumor xenografts or the formation of B16F10 melanoma lung metastasis. In contrast to NE-58051, risedronate did inhibit B02 breast cancer bone metastasis formation by reducing both bone destruction and skeletal tumor burden, indicating that the antitumor effect of bisphosphonates is achieved mainly through inhibition of osteoclast-mediated bone resorption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.